CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2025	Dec. 31, 2024
CURRENT ASSETS
Cash	$ 131,317	$ 513,443
Prepaid expenses	16,337	65,300
Due from Chromocell Corporation	40,400	40,400
Deferred offering costs	723,125	750,000
TOTAL CURRENT ASSETS	911,179	1,369,143
TOTAL ASSETS	911,179	1,369,143
CURRENT LIABILITIES
Accounts payable and accrued expenses	2,603,605	1,897,127
Loan payable, net of debt discount	2,371,540	2,054,202
Loan payable - related party, net of debt discount	131,868	131,868
TOTAL CURRENT LIABILITIES	5,107,013	4,083,197
TOTAL LIABILITIES	5,107,013	4,083,197
STOCKHOLDERS’ DEFICIT
Common stock, $0.0001 par value, 200,000,000 shares authorized, 6,183,562 and 6,103,813 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	621	613
Additional paid in capital	19,246,143	18,760,320
Accumulated deficit	(23,442,598)	(21,474,987)
TOTAL STOCKHOLDERS’ DEFICIT	(4,195,834)	(2,714,054)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	911,179	1,369,143
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred stock, value, issued
Series C Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred stock, value, issued

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.